Abbott today announced that UnitedHealthcare (UHC), the largest private health insurance company in the United States, has updated its ‘Implanted Electrical Stimulator for Spinal Cord’ medical policy to expand patient access to Abbott’s dorsal root ganglion (DRG) neurostimulation devices for people suffering from .
Abbott to Launch the NeuroSphere myPath Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
Abbott today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation or dorsal root ganglion therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well-being while trialing their …
Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. During the device trial period required before the permanent implant, the app allows patients to record their outcomes on pain and well